X

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B-Cell Lymphoma in the Rituximab Era

This retrospective study aimed to better define the characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.

Blood
01/07/2021
Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

The objective of this study is to evaluate the efficacy and safety of GemDOx with or without rituximab as salvage therapy in patients with relapsed or refractory DLBCL and PTCL.

01/01/2021
Primary Diffuse Large B-Cell Lymphoma of the Female Urethra

 

Primary urethral non-Hodgkin’s lymphoma is uncommon. This case study reports the case of a 52-year-old woman with a light red mass at the urethral orifice.

12/21/2020

Potential New Standard for High-Risk B-Cell Non-Hodgkin Lymphoma

DLBCL accounts for more than 60 percent of pediatric NHLs. Patients diagnosed with it have a 5-year survival rate of 63 percent for all disease stages combined.

Oncology Times - Latest Articles
12/20/2020
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

International Journal of Molecular Sciences
11/13/2020
Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort

DLBCL with MYC/BCL2 double-expression, a recently proposed poor prognostic group, can be easily identified by immunohistochemistry in routine clinical practice.

Cancers
11/09/2020
Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Despite advances in treatment and increasing knowledge of clinical importance of DLBCL subtype classification, socioeconomic disparities persist in the treatment of DLBCL in the US...

Blood
11/05/2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma

This study recently reported a new tool to help the early identification of ultra-high risk DLBCL patients.

Blood
11/05/2020
NUSAP1 Promotes Cell Proliferation Via the DNA Damage Response Pathway in Diffuse Large B-Cell Lymphoma

NUSAP1 has been shown to be highly expressed in a variety of tumors, involved in tumor occurrence, invasion, migration, and drug resistance.

Blood
11/05/2020
Real-World CAR-T Therapy Toxicity in Patients With DLBCL

This study explores the toxicity from axicabtagene ciloleucel in the real-world setting demonstrates the necessity for more studies exploring real-world experience and data to define...

Journal of Clinical Pathways
11/11/2020
Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab is an Fc-enhanced, humanized, monoclonal antibody that targets CD19, which is broadly expressed across B-cell malignancies, including DLBCL.

Blood
11/05/2020
Reductions in Rates of Surveillance Imaging in Patients With Diffuse Large B-Cell Lymphoma

Rates of surveillance imaging for survivors of DLBCL have declined following the ASH Choosing Wisely recommendations made in 2013.

Oncology Nurse Advisor
11/13/2020
Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway.

Epirubicin is a first-line chemotherapeutic drug for the clinical treatment of DLBCL, but the overexpression of multidrug resistance transporter proteins, especially P-glycoprotein...

Translational Oncology
01/01/2021
Gingival manifestation of a therapy-related acute myelomonocytic leukemia in a patient with previously treated with R–CHOP scheme for diffuse large B-cell lymphoma

In this case, a 58-year-old patient diagnosed with DLBCL and treated with the CHOP-R therapeutic scheme, developed after 4 years a widespread gingival enlargement...

Oral and Maxillofacial Surgery Cases
12/01/2020
Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.

In this study, the authors conducted a retrospective review of DLBCL tissues from patients with and without HIV infection to compare expression of AID and B-cell receptors...

AIDS
11/15/2020

source list reference

#7d60d9
#2694a4
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#42fc9a
#cc529a
#c59445
#c8cc0c
#e8085a
#97d1a0
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#49cde9
#c20fce
#d95d39